Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option.
Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Description of use of ceftaroline and ceftobiprole | description of patients and their PJI/BJI,conditions of use, adverse event |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Description of use of ceftaroline and ceftobiprole | Other | Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of use of ceftaroline and ceftobiprole : patients | type of patients: age, CMI | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
| Evaluation of use of ceftaroline: dosage | dosage,duration | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
| Evaluation of use of ceftaroline : PJI/BJI | description of the PJI/BJI treated by ceftaroline : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
| Evaluation of use of ceftobiprole: dosage | dosage, duration | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
| Evaluation of use of ceftobiprole: PJI/BJI | description of the PJI/BJI treated by ceftobiprole : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
| rate of failure under ceftaroline | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-related adverse events | description of adverse event under ceftaroline and/or ceftobiprole as assessed by CTCAE v4.0 | 2 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
patients having had a PJI or BJI treated whith ceftaroline and/or ceftobiprole treated at CRIOAc Lyon
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Lyon | 69004 | France |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C443755 | ceftobiprole |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| rate of failure under ceftobiprole | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |